Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HIF1a inhibition overcomes castration resistance

ABSTRACT: HIF1a inhibition overcomes castration resistance

PROVIDER: PRJNA892463 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

HIF1a inhibition overcomes castration resistance

Project description:We used single-cell RNA sequencing to understand castration resistance in a murine model of prostate cancer

2023-03-23 | GSE216158 | GEO

SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

Project description:SUMOylation inhibition overcomes dexamethasone resistance in multiple myeloma

| PRJNA687056 | ENA

T Cell Reinvigoration upon ACK1/TNK2 inhibition Overcomes Immune Resistance

Project description:T Cell Reinvigoration upon ACK1/TNK2 inhibition Overcomes Immune Resistance

| PRJNA872199 | ENA

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Project description:MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

| PRJNA786564 | ENA

Pharmaceutical inhibition of RAS overcomes cytokine mediated resistance to FLT3 inhibition in FLT3-ITD+ AML

Project description:Pharmaceutical inhibition of RAS overcomes cytokine mediated resistance to FLT3 inhibition in FLT3-ITD+ AML

| PRJNA1009040 | ENA

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells [France4]

Project description:MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells [France4]

| PRJNA786567 | ENA

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells [France3]

Project description:MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells [France3]

| PRJNA786565 | ENA

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells [LLC1]

Project description:MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells [LLC1]

| PRJNA786566 | ENA

Targeting UGCG overcomes resistance to lysosomal autophagy inhibition

Project description:Lysosomal autophagy inhibition (LAI) with hydroxychloroquine or DC661 can enhance cancer therapy, but tumor regrowth is common. To elucidate LAI resistance, proteomics and immunoblotting demonstrated that LAI induced lipid metabolism enzymes in multiple cancer cell lines. Lipidomics showed that LAI increased cholesterol, sphingolipids, and glycosphingolipids. These changes were associated with striking levels of GM1+ membrane microdomains (GMM) in plasma membranes and lysosomes. Inhibition of cholesterol/sphingolipid metabolism proteins enhanced LAI cytotoxicity. Targeting UDP-glucose ceramide glucosyltransferase (UGCG) synergistically augmented LAI cytotoxicity. While UGCG inhibition decreased LAI-induced GMM and augmented cell death, UGCG overexpression led to LAI resistance. Melanoma patients with high UGCG expression had significantly shorter disease-specific survival. The FDA-approved UGCG inhibitor eliglustat combined with LAI significantly inhibited tumor growth and improved survival in syngeneic tumors and a therapy-resistant patient-derived xenograft. These findings nominate UGCG as a new cancer target, and clinical trials testing UGCG inhibition in combination with LAI are warranted.

2022-03-08 | MSV000089020 | MassIVE